| AFP | Alpha fetoprotein |
| Ag/Ab | antigen/antibody test |
| AIDS | acquired immunodeficiency syndrome |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| ASHM | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine |
| BBVs | blood-borne viruses |
| CK | creatine kinase |
| eGFR | estimated glomerular filtration rate |
| EUC | Electrolytes, Urea, Creatinine |
| Fbc | Full Blood Count |
| FTC | emtricitabine |
| GP | general practitioner |
| HBV | hepatitis B virus |
| hCG | human chorionic gonadotropin |
| HCV | hepatitis C virus |
| HCW | healthcare worker |
| HIV | human immunodeficiency virus |
| HPC | high-prevalence country |
| IAI | insertive anal intercourse |
| iPrEx | Pre-exposure Prophylaxis Initiative |
| IVI | insertive vaginal intercourse |
| LFT | Liver Function Test |
| MSM | men who have sex with men |
| PBS | Pharmaceutical Benefits Scheme |
| urinary PCR | urine protein:creatinine ratio |
| PEP | post-exposure prophylaxis |
| PrEP | pre-exposure prophylaxis |
| PWID | people who inject drugs |
| RAI | receptive anal intercourse |
| RVI | receptive vaginal intercourse |
| s100 | a section of the Pharmaceutical Benefits Scheme which provides access to highly specialised drugs |
| Source individual | a person whose blood or other bodily substance may be a source of HIV exposure |
| STI | sexually transmissible infection |
| TAF | tenofovir alafenamide |
| TD | tenofovir disoproxil |
| TDF | tenofovir disoproxil fumarate |
| TGA | Therapeutic Goods Administration |
| U=U | undetectable equals untransmittable |
| Viraemic | ≥ 200 copies/ml of HIV detected on a blood test |
| VL | viral load |
| WB | Western blot assay |
Menu
